litlas
Log inCreate account

Christopher J. Logothetis

Active 1982–2025

203
Papers
39,629
Citations
100
h-index
197
i10-index

Citations

Citations per year for Christopher J. Logothetis1984: 1 citations1985: 2 citations1986: 1 citations1987: 4 citations1988: 2 citations1989: 4 citations1990: 7 citations1991: 10 citations1992: 10 citations1993: 12 citations1994: 47 citations1995: 43 citations1996: 43 citations1997: 36 citations1998: 52 citations1999: 55 citations2000: 62 citations2001: 82 citations2002: 80 citations2003: 106 citations2004: 122 citations2005: 150 citations2006: 154 citations2007: 145 citations2008: 124 citations2009: 107 citations2010: 161 citations2011: 195 citations2012: 191 citations2013: 375 citations2014: 417 citations2015: 424 citations2016: 434 citations2017: 457 citations2018: 521 citations2019: 1,278 citations2020: 1,342 citations2021: 1,446 citations2022: 1,011 citations2023: 764 citations2024: 1,223 citations2025: 512 citations2026: 13 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,671 citing papers, 30.7% of this breakdownChina: 1,379 citing papers, 9.1% of this breakdownUnited Kingdom: 952 citing papers, 6.3% of this breakdownItaly: 746 citing papers, 4.9% of this breakdownGermany: 718 citing papers, 4.7% of this breakdownCanada: 707 citing papers, 4.7% of this breakdownFrance: 596 citing papers, 3.9% of this breakdownAustralia: 458 citing papers, 3% of this breakdownSpain: 436 citing papers, 2.9% of this breakdownJapan: 406 citing papers, 2.7% of this breakdownNetherlands: 400 citing papers, 2.6% of this breakdownSwitzerland: 319 citing papers, 2.1% of this breakdown
0%30.7%Other 22.4%

Institutions

Fields

  • Medicine66.9%
  • Biochemistry, Genetics and Molecular Biology25.1%
  • Immunology and Microbiology4.5%
  • Neuroscience0.5%
  • Engineering0.5%
  • Materials Science0.4%
  • Other2.1%

Topics

  • Prostate Cancer Treatment and Research13.3%
  • Prostate Cancer Diagnosis and Treatment5.9%
  • Cancer Immunotherapy and Biomarkers4.8%
  • Radiopharmaceutical Chemistry and Applications3.3%
  • Immunotherapy and Immune Responses2.5%
  • Cancer, Lipids, and Metabolism2.3%
  • Other67.9%

Coauthors

All papers

Open in search
  1. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Authors: Howard I. Scher, Michael J. Morris, Walter M. Stadler, Celestia S. Higano, Ethan Basch, Karim Fizazi, Emmanuel S. Antonarakis, Tomasz M. Beer, Michael A. Carducci, Kim N., Paul G. Corn, Johann S. de Bono, Robert Dreicer, Daniel J. George, Elisabeth I. Heath, Maha Hussain, Wm. Kevin Kelly, Glenn Liu, Christopher J. Logothetis, David M. Nanus, Mark N. Stein, Dana E. Rathkopf, Susan F. Slovin, Charles J. Ryan, Oliver Sartor, Eric J. Small, Matthew Raymond Smith, Cora N. Sternberg, Mary-Ellen Taplin, George Wilding, Peter S. Nelson, Lawrence H. Schwartz, Susan Halabi, Philip W. Kantoff, Andrew J. Armstrong - Journal of Clinical Oncology 2016 cited by 1,603

  2. Abiraterone and Increased Survival in Metastatic Prostate Cancer

    Authors: Johann S. de Bono, Christopher J. Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, Kim N., Robert J. Jones, Oscar B. Goodman, Fred Saad, John Staffurth, Paul N. Mainwaring, Stephen Harland, Thomas W. Flaig, Thomas E. Hutson, Tina Cheng, Helen Patterson, John D. Hainsworth, Charles J. Ryan, Cora N. Sternberg, Susan Ellard, Aude Fléchon, Mansoor N. Saleh, Mark C. Scholz, Eleni Efstathiou, Andrea Zivi, Diletta Bianchini, Yohann Loriot, Nicole Chieffo, Thian Kheoh, Christopher M. Haqq, Howard I. Scher - New England Journal of Medicine 2011 cited by 4,394

  3. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

    Authors: Charles J. Ryan, Matthew R. Smith, Johann S. de Bono, Arturo Molina, Christopher J. Logothetis, Paul de Souza, Karim Fizazi, Paul N. Mainwaring, Josep M. Piulats, Siobhan Ng, Joan Carles, Peter F.A. Mulders, Ethan Basch, Eric J. Small, Fred Saad, Dirk Schrijvers, Hendrik Van Poppel, Som D. Mukherjee, H. Suttmann, Winald R. Gerritsen, Thomas W. Flaig, Daniel J. George, Evan Y. Yu, Eleni Efstathiou, Allan J. Pantuck, Eric Winquist, Celestia S. Higano, Mary-Ellen Taplin, Youn Park, Thian Kheoh, Thomas W. Griffin, Howard I. Scher, Dana E. Rathkopf - New England Journal of Medicine 2012 cited by 2,795

  4. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

    Authors: Charles J. Ryan, Matthew R. Smith, Karim Fizazi, Fred Saad, Peter F.A. Mulders, Cora N. Sternberg, Kurt Miller, Christopher J. Logothetis, Neal D. Shore, Eric J. Small, Joan Carles, Thomas W. Flaig, Mary-Ellen Taplin, Celestia S. Higano, Paul de Souza, Johann S. de Bono, Thomas W. Griffin, Peter De Porre, Margaret K. Yu, Youn C. Park, Jinhui Li, Thian Kheoh, Vahid Naini, Arturo Molina, Dana E. Rathkopf - The Lancet Oncology 2015 cited by 1,354

  5. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

    Authors: Jianjun Gao, John F. Ward, Curtis A. Pettaway, Lewis Z. Shi, Sumit K. Subudhi, Luis M. Vence, Hao Zhao, Jianfeng Chen, Hong Chen, Eleni Efstathiou, Patricia Troncoso, James P. Allison, Christopher J. Logothetis, Ignacio I. Wistuba, Manuel A. Sepúlveda, Jingjing Sun, Jennifer A. Wargo, Jorge Blando, Padmanee Sharma - Nature Medicine 2017 cited by 592

  6. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

    Authors: Tomasz M. Beer, Eugene D. Kwon, Charles G. Drake, Karim Fizazi, Christopher J. Logothetis, Gwénaëlle Gravis, Vinod Ganju, Jonathan Polikoff, Fred Saad, Piotr Humanski, Josep M. Piulats, Pablo González Mella, Siobhan Ng, Dirk Jaeger, Francis Parnis, Fábio Franke, Javier Puente, Roman Carvajal, Lisa Sengeløv, M. Brent McHenry, Arvind Varma, Alfonsus JM. van den Eertwegh, Winald R. Gerritsen - Journal of Clinical Oncology 2016 cited by 754

  7. Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression

    Authors: Guocan Wang, Xin Lü, Prasenjit Dey, Pingna Deng, Chia-Chin Wu, Shan Jiang, Zhuangna Fang, Kun Zhao, Ramakrishna Konaparthi, Sujun Hua, Jianhua Zhang, Elsa M. Li-Ning-Tapia, Avnish Kapoor, Chang‐Jiun Wu, Neelay Bhaskar Patel, Zhenglin Guo, Vandhana Ramamoorthy, Trang N. Tieu, Tim Heffernan, Di Zhao, Xiaoying Shang, Sunada Khadka, Pingping Hou, Baoli Hu, Eun‐Jung Jin, Wantong Yao, Xiaolu Pan, Zhihu Ding, Yanxia Shi, Li Li, Qing Chang, Patricia Troncoso, Christopher J. Logothetis, Mark J. McArthur, Lynda Chin, Yin Wang, Ronald A. DePinho - Cancer Discovery 2015 cited by 553

  8. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

    Authors: Karim Fizazi, Howard I. Scher, Arturo Molina, Christopher J. Logothetis, Kim N., Robert J. Jones, John Staffurth, Scott North, Nicholas J. Vogelzang, Fred Saad, Paul N. Mainwaring, Stephen Harland, Oscar B. Goodman, Cora N. Sternberg, Jin Hui Li, Thian Kheoh, Christopher M. Haqq, Johann S. de Bono - The Lancet Oncology 2012 cited by 1,387

  9. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

    Authors: Susan Halabi, William Kevin Kelly, Hua Ma, Hao Zhou, Nicole Solomon, Karim Fizazi, Catherine M. Tangen, Mark Rosenthal, Daniel P. Petrylak, Maha Hussain, Nicholas J. Vogelzang, Ian M. Thompson, Kim N., Johann S. de Bono, Andrew J. Armstrong, Mario A. Eisenberger, Abderrahim Fandi, Shaoyi Li, John C. Araujo, Christopher J. Logothetis, David I. Quinn, Michael J. Morris, Celestia S. Higano, Ian F. Tannock, Eric J. Small - Journal of Clinical Oncology 2016 cited by 463

  10. Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer

    Authors: Likun Li, Styliani Karanika, Guang Yang, Jiangxiang Wang, Sanghee Park, Bradley M. Broom, Ganiraju C. Manyam, Wenhui Wu, Yong Luo, Spyridon P. Basourakos, Jian H. Song, Gary E. Gallick, Theodoros Karantanos, Dimitrios Korentzelos, Abul Kalam Azad, Jeri Kim, Paul G. Corn, Ana M. Aparicio, Christopher J. Logothetis, Patricia Troncoso, Timothy P. Heffernan, Carlo Toniatti, Hyun‐Sung Lee, Ju‐Seog Lee, Xuemei Zuo, Wenjun Chang, Jianhua Yin, Timothy C. Thompson - Science Signaling 2017 cited by 304

  11. Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

    Authors: Ana M. Aparicio, Andrea Harzstark, Paul G. Corn, Sijin Wen, John C. Araujo, Shi‐Ming Tu, Lance C. Pagliaro, Jeri Kim, Randall E. Millikan, Charles J. Ryan, Nizar M. Tannir, Amado J. Zurita, Paul Mathew, Wadih Arap, Patricia Troncoso, Peter F. Thall, Christopher J. Logothetis - Clinical Cancer Research 2013 cited by 466

  12. CTLA-4 blockade increases IFNγ-producing CD4 + ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patients

    Authors: Chrysoula I. Liakou, Ashish M. Kamat, Derek Ng Tang, Hong Chen, Jingjing Sun, Patricia Troncoso, Christopher J. Logothetis, Padmanee Sharma - National Academy of Sciences, Proceedings of the National Academy of Sciences 2008 cited by 538

  13. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

    Authors: Christopher P. Vellano, Michael G. White, Miles C. Andrews, Manoj Chelvanambi, Russell G. Witt, Joseph R. Daniele, Mark Titus, Jennifer L. McQuade, Fabio Conforti, Elizabeth M. Burton, Matthew Lastrapes, Gabriel O Ologun, Alexandria P. Cogdill, Golnaz Morad, Peter A. Prieto, Alexander J. Lazar, Yanshuo Chu, Guangchun Han, M.A. Wadud Khan, Beth A. Helmink, Michael A. Davies, Rodabe N. Amaria, Jeffrey J. Kovacs, Scott E. Woodman, Sapna P. Patel, Patrick Hwu, Michael Peoples, Jeffrey E. Lee, Zachary A. Cooper, Haifeng Zhu, Guang R. Gao, Hiya Banerjee, Mike Lau, Jeffrey E. Gershenwald, Anthony Lucci, Emily Z. Keung, Merrick I. Ross, Laura Pala, Eleonora Pagan, Rossana Lazcano Segura, Qian Liu, Mikayla Borthwick, Eric Lau, Melinda S. Yates, Shannon N. Westin, Khalida Wani, Michael T. Tetzlaff, Lauren E. Haydu, Mikhila Mahendra, Xiao-Yan Ma, Christopher J. Logothetis, Zachary Kulstad, Sarah B. Johnson, Courtney W. Hudgens, Ningping Feng, Lorenzo Federico, Georgina V. Long, P. Andrew Futreal, Swathi Arur, Hussein A. Tawbi, Amy E. Moran, Linghua Wang, Timothy P. Heffernan, Joseph R. Marszalek, Jennifer A. Wargo - Nature 2022 cited by 130

  14. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors

    Authors: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, Eugene D. Kwon, Howard I. Scher, Winald R. Gerritsen, Alberto Bossi, Alfons J.M. van den Eertwegh, Michael Krainer, Nadine Houédé, Ricardo Vieira Santos, Hakim Mahammedi, Siobhan Ng, Riccardo Danielli, Fábio Franke, Santhanam Sundar, Neeraj Agarwal, Andries M. Bergman, Tudor–Eliade Ciuleanu, Ernesto Korbenfeld, Lisa Sengeløv, Steinbjørn Hansen, M. Brent McHenry, Allen Chen, Christopher J. Logothetis - European Urology 2020 cited by 175

  15. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    Authors: Silke Gillessen, Alberto Bossi, Ian D. Davis, Johann S. de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, Neal D. Shore, Eric J. Small, Matthew R. Smith, Christopher J. Sweeney, Bertrand Tombal, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Alberto Briganti, Robert G. Bristow, Muhammad Bulbul, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N., Simon Chowdhury, Caroline S. Clarke, Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Rosalind A. Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Daniel J. George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia S. Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raya Leibowitz‐Amit, Christopher J. Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Alicia K. Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver A. Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki and 18 more - European Urology 2022 cited by 118

  16. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers

    Authors: Ana M. Aparicio, Li Shen, Elsa Li Ning Tapia, Jing‐Fang Lu, Hsiang-Chun Chen, Jiexin Zhang, Guanglin Wu, Xuemei Wang, Patricia Troncoso, Paul G. Corn, Timothy C. Thompson, Bradley M. Broom, Keith Baggerly, Sankar N. Maity, Christopher J. Logothetis - Clinical Cancer Research 2015 cited by 290

  17. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial

    Authors: Paul G. Corn, Elisabeth I. Heath, Amado J. Zurita, Naveen Ramesh, Lianchun Xiao, Emi Sei, Elsa M. Li-Ning-Tapia, Shi‐Ming Tu, Sumit K. Subudhi, Jennifer Wang, Xuemei Wang, Eleni Efstathiou, Timothy C. Thompson, Patricia Troncoso, Nicholas E. Navin, Christopher J. Logothetis, Ana M. Aparicio - The Lancet Oncology 2019 cited by 202

  18. Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer Stem Cell Traits and Cancer Progression

    Authors: Chia‐Hsin Chan, John Kenneth Morrow, Chien‐Feng Li, Yuan Gao, Guoxiang Jin, Asad Moten, Loren Stagg, John E. Ladbury, Zhen Cai, Dazhi Xu, Christopher J. Logothetis, Mien‐Chie Hung, Shuxing Zhang, Hui‐Kuan Lin - Cell 2013 cited by 393

  19. Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors

    Authors: John C. Araujo, Christopher J. Logothetis - Cancer Treatment Reviews 2010 cited by 245

  20. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers

    Authors: Omar Alhalabi, Jianfeng Chen, Yuxue Zhang, Yang Lü, Qi Wang, Sumankalai Ramachandran, Rebecca S. Tidwell, Guangchun Han, Xinmiao Yan, Jieru Meng, Ruiping Wang, Anh Hoang, Wei‐Lien Wang, Jian H. Song, Lidia López, Alex Andreev-Drakhlin, Arlene O. Siefker‐Radtke, Xinqiao Zhang, William F. Benedict, Amishi Y. Shah, Jennifer Wang, Pavlos Msaouel, Miao Zhang, Charles C. Guo, Bogdan Czerniak, Carmen Behrens, Luisa M. Solis Soto, Vassiliki A. Papadimitrakopoulou, Jeff Lewis, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, J. Jack Lee, Jack A. Roth, Stephen G. Swisher, Ignacio I. Wistuba, John V. Heymach, Jing Wang, Matthew T. Campbell, Eleni Efstathiou, Mark Titus, Christopher J. Logothetis, Thai H. Ho, Jianjun Zhang, Linghua Wang, Jianjun Gao - Nature Communications 2022 cited by 72

  21. Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

    Authors: Bradley Curtis Carthon, Jedd D. Wolchok, Jianda Yuan, Ashish M. Kamat, Derek S. Ng Tang, Jingjing Sun, Geoffrey Y. Ku, Patricia Troncoso, Christopher J. Logothetis, James P. Allison, Padmanee Sharma - Clinical Cancer Research 2010 cited by 461

  22. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities

    Authors: Sumit K. Subudhi, Ana M. Aparicio, Jianjun Gao, Amado J. Zurita, John C. Araujo, Christopher J. Logothetis, Salahaldin A. Tahir, Brinda Rao Korivi, Rebecca Slack, Luis M. Vence, Ryan Emerson, Erik Yusko, Marissa Vignali, Harlan Robins, Jingjing Sun, James P. Allison, Padmanee Sharma - National Academy of Sciences, Proceedings of the National Academy of Sciences 2016 cited by 233

  23. Aggressive Variants of Castration-Resistant Prostate Cancer

    Authors: Himisha Beltran, Scott A. Tomlins, Ana M. Aparicio, Vivek Arora, David S. Rickman, Gustavo Ayala, Jiaoti Huang, Lawrence D. True, Martin Gleave, Howard R. Soule, Christopher J. Logothetis, Mark A. Rubin - Clinical Cancer Research 2014 cited by 426

  24. Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis

    Authors: Hyun Ho Han, Yan Wang, Josué Curto, Sreeharsha Gurrapu, Sara Laudato, Alekya Rumandla, Goutam Chakraborty, Xiaobo Wang, Hong Chen, Yan Jiang, Dhiraj Kumar, Emily G. Caggiano, Monica Capogiri, Boyu Zhang, Yan Ji, Sankar N. Maity, Min Hu, Shanshan Bai, Ana M. Aparicio, Eleni Efstathiou, Christopher J. Logothetis, Nicholas E. Navin, Nora M. Navone, Yu Chen, Filippo G. Giancotti - Cell Reports 2022 cited by 69